Changes in the composition of the pneumococcal population and in IPD incidence in The Netherlands after the implementation of the 7-valent pneumococcal conjugate vaccine

Vaccine

Volumn 30, Issue 52, 2012, Pages 7644-7651

  Elberse, Karin E M ^a   van der Heide, Han G J ^a   Witteveen, Sandra ^a   van de Pol, Ingrid ^a   Schot, Corrie S ^a   van der Ende, Arie ^b   Berbers, Guy A M ^a   Schouls, Leo M ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

IPD incidence; MLVA; Molecular typing; Pneumococcal conjugate vaccine; Pneumococcal population; Pneumococcus; Temporal changes

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CAPSULAR SEQUENCE TYPING; CHILD; FEMALE; GENETIC PROCEDURES; HEALTH CARE PLANNING; HUMAN; IMMUNITY; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; MOLECULAR TYPING; MULTIPLE LOCUS VARIABLE NUMBER TANDEM REPEAT ANALYSIS; NETHERLANDS; NEWBORN; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VARIABLE NUMBER OF TANDEM REPEAT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTERIAL CAPSULES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MENINGITIS, PNEUMOCOCCAL; MIDDLE AGED; MINISATELLITE REPEATS; MOLECULAR EPIDEMIOLOGY; MULTILOCUS SEQUENCE TYPING; NETHERLANDS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; YOUNG ADULT;

EID: 84870485880     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.04.021     Document Type: Article

References (40)

1. Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. Journal of Clinical Microbiology 1995, 33(10):2759-2762.
2. Park I.H., Pritchard D.G., Cartee R., Brandao A., Brandileone M.C., Nahm M.H. Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. Journal of Clinical Microbiology 2007, 45(4):1225-1233.
3. Austrian R. Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention. Reviews of Infectious Diseases 1981, 3(March-April (Suppl.)):S1-S17.
4. Kadioglu A., Weiser J.N., Paton J.C., Andrew P.W. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nature Reviews Microbiology 2008, 6(April (4)):288-301.
5. Douglas R.M., Paton J.C., Duncan S.J., Hansman D.J. Antibody response to pneumococcal vaccination in children younger than five years of age. Journal of Infectious Diseases 1983, 148(July (1)):131-137.
6. Sell S.H., Wright P.F., Vaughn W.K., Thompson J., Schiffman G. Clinical studies of pneumococcal vaccines in infants. I. Reactogenicity and immunogenicity of two polyvalent polysaccharide vaccines. Reviews of Infectious Diseases 1981, 3(March-April (Suppl.)):S97-S107.
7. Wright P.F., Sell S.H., Vaughn W.K., Andrews C., McConnell K.B., Schiffman G Clinical studies of pneumococcal vaccines in infants. II. Efficacy and effect on nasopharyngeal carriage. Reviews of Infectious Diseases 1981, 3(March-April (Suppl.)):S108-S112.
8. Avery O.T., Goebel W.F. Chemo-immunological studies on conjugated carbohydrate-proteins. II. Immunological specificity of synthetic sugar-protein antigens. Journal of Experimental Medicine 1929, 50(September (4)):533-550.
9. Siber G.R. Pneumococcal disease: prospects for a new generation of vaccines. Science 1994, 265(September (5177)):1385-1387.
10. Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction-eight states, 1998-2005. MMWR Morbidity and Mortality Weekly Report 2008;57(February (6)):144-8.
11. Hicks L.A., Harrison L.H., Flannery B., Hadler J.L., Schaffner W., Craig A.S., et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. Journal of Infectious Diseases 2007, 196(9):1346-1354.
12. Moore M.R., Gertz R.E., Woodbury R.L., Barkocy-Gallagher G.A., Schaffner W., Lexau C., et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. Journal of Infectious Diseases 2008, 197(7):1016-1027.
13. Singleton R.J., Hennessy T.W., Bulkow L.R., Hammitt L.L., Zulz T., Hurlburt D.A., et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007, 297(16):1784-1792.
14. Reinert R., Jacobs M.R., Kaplan S.L. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine 2010, 28(June (26)):4249-4259.
15. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. New England Journal of Medicine 2003, 348(May (18)):1737-1746.
16. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children Northern California Kaiser Permanente Vaccine Study Center Group. Pediatric Infectious Disease Journal 2000, 19(March (3)):187-195.
17. Lexau C.A., Lynfield R., Danila R., Pilishvili T., Facklam R., Farley M.M., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005, 294(October (16)):2043-2051.
18. O'Brien K.L., Moulton L.H., Reid R., Weatherholtz R., Oski J., Brown L., et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 2003, 362(August (9381)):355-361.
19. Whitney C.G., Pilishvili T., Farley M.M., Schaffner W., Craig A.S., Lynfield R., et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006, 368(October (9546)):1495-1502.
20. Jansen A.G., Rodenburg G.D., van der Ende A., van Alphen L., Veenhoven R.H., Spanjaard L., et al. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clinical Infectious Diseases 2009, 49(July (2)):e23-e29.
21. Rodenburg G.D., de Greeff S.C., Jansen A.G., de Melker H.E., Schouls L.M., Hak E., et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, The Netherlands. Emerging Infectious Diseases 2010, 16(May (5)):816-823.
22. Coffey T.J., Dowson C.G., Daniels M., Zhou J., Martin C., Spratt B.G., et al. Horizontal transfer of multiple penicillin-binding protein genes, and capsular biosynthetic genes, in natural populations of Streptococcus pneumoniae. Molecular Microbiology 1991, 5(September (9)):2255-2260.
23. Pai R., Moore M.R., Pilishvili T., Gertz R.E., Whitney C.G., Beall B. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. Journal of Infectious Diseases 2005, 192(December (11)):1988-1995.
24. Brueggemann A.B., Pai R., Crook D.W., Beall B. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathogens 2007, 3(11):e168.
25. Elberse K.E., van de Pol I., Witteveen S., van der Heide H.G., Schot C.S., van Dijk A., et al. Population structure of invasive Streptococcus pneumoniae in The Netherlands in the pre-vaccination era assessed by MLVA and capsular sequence typing. PLoS One 2011, 6(5):e20390.
26. Elberse K.E., Nunes S., Sa-Leao R., van der Heide H.G., Schouls L.M. Multiple-locus variable number tandem repeat analysis for Streptococcus pneumoniae: comparison with PFGE and MLST. PLoS One 2011, 6(5):e19668.
27. Lund E. Laboratory diagnosis of pneumococcus infections. Bulletin of the World Health Organization 1960, 23:5-13.
28. Austrian R. The quellung reaction, a neglected microbiologic technique. Mount Sinai Journal of Medicine 1976, 43(6):699-709.
29. Enright M.C., Spratt B.G. A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease. Microbiology 1998, 144(Pt 11):3049-3060.
30. Fenoll A., Granizo J.J., Aguilar L., Gimenez M.J., Aragoneses-Fenoll L., Hanquet G., et al. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. Journal of Clinical Microbiology 2009, 47(April (4)):1012-1020.
31. Foster D., Knox K., Walker A.S., Griffiths D.T., Moore H., Haworth E., et al. Invasive pneumococcal disease: epidemiology in children and adults prior to implementation of the conjugate vaccine in the Oxfordshire region, England. Journal of Medical Microbiology 2008, 57(April (Pt 4)):480-487.
32. Harboe Z.B., Benfield T.L., Valentiner-Branth P., Hjuler T., Lambertsen L., Kaltoft M., et al. Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clinical Infectious Diseases 2010, 50(February (3)):329-337.
33. Beall B., McEllistrem M.C., Gertz R.E., Wedel S., Boxrud D.J., Gonzalez A.L., et al. Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. Journal of Clinical Microbiology 2006, 44(March (3)):999-1017.
34. Lipsitch M., O'Neill K., Cordy D., Bugalter B., Trzcinski K., Thompson C.M., et al. Strain characteristics of Streptococcus pneumoniae carriage and invasive disease isolates during a cluster-randomized clinical trial of the 7-valent pneumococcal conjugate vaccine. Journal of Infectious Diseases 2007, 196(October (8)):1221-1227.
35. Chiou A.C., Andrade S.S., Almeida S.C., Zanella R.C., Andrade A.L., Brandileone M.C. Molecular assessment of invasive Streptococcus pneumoniae serotype 1 in Brazil: evidence of clonal replacement. Journal of Medical Microbiology 2008, 57(July (Pt 7)):839-844.
36. Jacobs M.R., Good C.E., Bajaksouzian S., Windau A.R. Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine. Clinical Infectious Diseases 2008, 47(December (11)):1388-1395.
37. Enright M.C., Fenoll A., Griffiths D., Spratt B.G. The three major Spanish clones of penicillin-resistant Streptococcus pneumoniae are the most common clones recovered in recent cases of meningitis in Spain. Journal of Clinical Microbiology 1999, 37(October (10)):3210-3216.
38. McGee L., McDougal L., Zhou J., Spratt B.G., Tenover F.C., George R., et al. Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network. Journal of Clinical Microbiology 2001, 39(July (7)):2565-2571.
39. Elberse K., Witteveen S., van der Heide H., van de Pol I., Schot C., van der Ende A., et al. Sequence diversity within the capsular genes of Streptococcus pneumoniae serogroup 6 and 19. PLoS One 2011, 6(9):e25018.
40. Weinberger D.M., Trzcinski K., Lu Y.J., Bogaert D., Brandes A., Galagan J., et al. Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathogens 2009, 5(June (6)):e1000476.